Benzinga | Nov 12, 2020 07:10AM EST

ADC Therapeutics Q3 EPS $(0.29) Beats $(0.81) Estimate

ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.81) by 64.2 percent.